Lymphatic vessel density is associated with CD8+ T cell infiltration and immunosuppressive factors in human melanoma.
Bordry NClinical Tumor Biology and Immunotherapy Group, Department of Oncology and Ludwig Cancer Research, University of Lausanne (UNIL), Lausanne, Switzerland.
Broggi MASInstitute of Bioengineering and Swiss Institute for Experimental Cancer Research (ISREC), School of Life Sciences, Ecole Polytechnique Fédérale de Lausanne, Lausanne, Switzerland.
de Jonge KClinical Tumor Biology and Immunotherapy Group, Department of Oncology and Ludwig Cancer Research, University of Lausanne (UNIL), Lausanne, Switzerland.
Schaeuble KClinical Tumor Biology and Immunotherapy Group, Department of Oncology and Ludwig Cancer Research, University of Lausanne (UNIL), Lausanne, Switzerland.
Gannon PODepartment of Oncology, Lausanne University Hospital Center (CHUV) and University of Lausanne, Lausanne, Switzerland.
Foukas PGDepartment of Oncology, Lausanne University Hospital Center (CHUV) and University of Lausanne, Lausanne, Switzerland.
Danenberg EDepartment of Oncology, Lausanne University Hospital Center (CHUV) and University of Lausanne, Lausanne, Switzerland.
Romano EDepartment of Oncology, Lausanne University Hospital Center (CHUV) and University of Lausanne, Lausanne, Switzerland.
Baumgaertner PClinical Tumor Biology and Immunotherapy Group, Department of Oncology and Ludwig Cancer Research, University of Lausanne (UNIL), Lausanne, Switzerland.
Fankhauser MInstitute of Bioengineering and Swiss Institute for Experimental Cancer Research (ISREC), School of Life Sciences, Ecole Polytechnique Fédérale de Lausanne, Lausanne, Switzerland.
Wald NClinical Tumor Biology and Immunotherapy Group, Department of Oncology and Ludwig Cancer Research, University of Lausanne (UNIL), Lausanne, Switzerland.
Cagnon LDepartment of Oncology, Lausanne University Hospital Center (CHUV) and University of Lausanne, Lausanne, Switzerland.
Abed-Maillard SDepartment of Oncology, Lausanne University Hospital Center (CHUV) and University of Lausanne, Lausanne, Switzerland.
Maby-El Hajjami HClinical Tumor Biology and Immunotherapy Group, Department of Oncology and Ludwig Cancer Research, University of Lausanne (UNIL), Lausanne, Switzerland.
Murray TClinical Tumor Biology and Immunotherapy Group, Department of Oncology and Ludwig Cancer Research, University of Lausanne (UNIL), Lausanne, Switzerland.
Ioannidou KClinical Tumor Biology and Immunotherapy Group, Department of Oncology and Ludwig Cancer Research, University of Lausanne (UNIL), Lausanne, Switzerland.
Letovanec IDepartment of Pathology, CHUV, Lausanne, Switzerland.
Yan PDepartment of Pathology, CHUV, Lausanne, Switzerland.
Michielin ODepartment of Oncology, Lausanne University Hospital Center (CHUV) and University of Lausanne, Lausanne, Switzerland.
Matter MDepartment of Oncology, Lausanne University Hospital Center (CHUV) and University of Lausanne, Lausanne, Switzerland.
Swartz MAInstitute of Bioengineering and Swiss Institute for Experimental Cancer Research (ISREC), School of Life Sciences, Ecole Polytechnique Fédérale de Lausanne, Lausanne, Switzerland.
Speiser DEClinical Tumor Biology and Immunotherapy Group, Department of Oncology and Ludwig Cancer Research, University of Lausanne (UNIL), Lausanne, Switzerland.
English
Increased density of tumor-associated lymphatic vessels correlates with poor patient survival in melanoma and other cancers, yet lymphatic drainage is essential for initiating an immune response. Here we asked whether and how lymphatic vessel density (LVD) correlates with immune cell infiltration in primary tumors and lymph nodes (LNs) from patients with cutaneous melanoma. Using immunohistochemistry and quantitative image analysis, we found significant positive correlations between LVD and CD8+ T cell infiltration as well as expression of the immunosuppressive molecules inducible nitric oxide synthase (iNOS) and 2,3-dioxygénase (IDO). Interestingly, similar associations were seen in tumor-free LNs adjacent to metastatic ones, indicating loco-regional effects of tumors. Our data suggest that lymphatic vessels play multiple roles at tumor sites and LNs, promoting both T cell infiltration and adaptive immunosuppressive mechanisms. Lymph vessel associated T cell infiltration may increase immunotherapy success rates provided that the treatment overcomes adaptive immune resistance.